ArticleCureus2025
Comprehensive Genome Profiling Test in Japanese Patients With Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2025 at the 112Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCastration-resistant prostate cancer (CRPC) represents a significant difficulty in oncology, with limited treatment options and decreasing survival rates. The comprehensive genomic profiling (CGP) test has appeared as a promising tool for personalizing treatment according to the genetic characteristics of tumors. In Japan, the incidence of prostate cancer (PC) has sharply increased, making it crucial to investigate effective therapies informed by genomic data.
methodsThis study retrospectively analyzed data from 30 patients who underwent the CGP test at Kanazawa University from March 2020 to February 2024. Patient information, including age, clinical stage, and previous treatments, was collected. The CGP tests were conducted on the tumor and blood specimens using FoundationOne® CDx. Survival analysis was conducted using the Kaplan-Meier method, with a significance level set at a
resultsGenomic mutations were detected in 27 patients (90%), predominantly TP53 (19 cases) and PTEN mutations (10 cases). Five patients received treatment based on the CGP results but with no significant difference in overall survival (OS) between the treated and untreated groups (
conclusionsThe CGP test revealed critical genetic mutations in patients with CRPC and highlighted the poor prognosis associated with CDK12 mutations. The results underscore the necessity for novel therapies tailored to these genetic profiles, emphasizing the role of the CGP in improving treatment personalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.